Peanut allergy has more approved and in-development treatment options than almost any other food allergy, which sounds like good news, and mostly is. But the path here has been unusually bumpy: one approved drug changed corporate hands at a steep financial loss, and one promising delivery method spent five years in regulatory limbo after an outright rejection. This is the real story behind the options available today.
Looking for treatment options for peanut allergy?
Browse open peanut allergy clinical trials near you! We'll handle the follow-up.
What's approved right now, in plain terms
Palforzia (approved January 2020, expanded to ages 1-3 in July 2024) works by giving peanut protein in small, carefully increasing doses over months, under medical supervision, to build tolerance. It reduces the severity of a reaction to accidental exposure. It does not mean someone can eat peanuts freely.
Omalizumab (approved February 2024) takes a different approach entirely: instead of building tolerance to peanut specifically, it blocks the immune signal behind allergic reactions to any food. It's especially relevant if peanut is one of several allergies someone has.
The patch that got rejected, then came back
The Viaskin peanut patch is a skin patch that slowly exposes the immune system to tiny amounts of peanut protein, without anyone eating it. In August 2020, the FDA didn`t approve it. The patch wasn't sticking to skin well enough, and the FDA wanted more proof it worked and more details about how it's made. Nothing about safety was the problem. DBV Technologies, the company behind it, then spent five years fixing the patch and running new tests.
In December 2025, a new large study showed real results: 46.6% of children using the patch could safely handle a real peanut exposure after 12 months, compared to only 14.8% of kids on the placebo patch. DBV now wants to try for approval again. The exact filing date has moved a few times already, since the FDA keeps asking for the data to be organized differently. Right now, the company expects to file sometime in the second half of 2026, with a separate, later request planned for kids ages 1 to 3. As of today, the patch is still not approved.
What Palforzia's ownership history says about this field
Nestlé bought Palforzia's maker, a company called Aimmune Therapeutics, for over $2 billion in 2020. Palforzia was the first approved peanut allergy treatment, and Nestlé expected it to sell really well. By 2023, sales were much slower than they'd hoped, so Nestlé sold the drug to another company, Stallergenes Greer, at a big loss. The drug itself wasn't the problem. The real issue was how much work it took to use: daily doses, repeated visits to the doctor's office to slowly increase the amount, and ongoing check-ins. That was more than a lot of families could keep up with. The lesson here: getting FDA approval doesn't automatically mean a treatment is easy to fit into daily life.
What researchers are studying now
- Multi-allergen oral immunotherapy. Because peanut allergy so often coexists with other food allergies, trials like ADP101 are testing whether one regimen can desensitize people to several allergens, including peanut, at once, rather than treating peanut in isolation.
- Biologics alongside oral immunotherapy. Trials are testing whether adding a biologic like omalizumab or dupilumab to peanut OIT can reduce the side effects that cause people to quit treatment partway through, historically one of OIT's biggest practical limitations.
- Sublingual approaches remain a smaller research track. Peanut-specific sublingual immunotherapy (under-the-tongue drops rather than swallowed protein) has shown modest effects in past studies and continues in smaller trials, generally with less dramatic results than oral immunotherapy so far.
Why peanut allergy research is unusually hard
The severity problem. Peanut is the leading cause of fatal food allergy reactions, so trials testing any new exposure-based approach, patches, powders, or otherwise, need extensive safety monitoring, which slows recruitment and adds cost compared to lower-risk research.
The adherence problem. Palforzia's commercial struggles are really a research lesson: even a treatment that works in a trial can fail to translate into real-world use if the daily burden is too high. Newer research increasingly measures whether people can actually stick with a regimen, not just whether it works under trial conditions.
The all-or-nothing history problem. For years, oral immunotherapy was really the only serious research avenue, so a rejection like Viaskin's 2020 setback carried outsized weight for the whole field. A more diversified pipeline today, patches, biologics, multi-allergen approaches, means no single setback derails peanut allergy research the way it might have a decade ago.
Common myths, cleared up
"A skin patch sounds gentler, so it must be safer than eating the protein."
Both approaches carry real risks and both require medical supervision; a patch avoids ingestion but doesn't eliminate the possibility of a reaction.
"If Palforzia works, it means my child is basically cured."
Approved treatments reduce reaction severity to accidental exposure; they aren't a cure, and avoidance guidance typically still applies afterward.
"Peanut allergy trials only enroll kids."
Many focus on children since that's when most peanut allergy is diagnosed and treated, but adult-specific and mixed-age trials exist too, including within the multi-food and biologic combination research described above.
How to find a peanut allergy study through our platform
Search current studies by age group and by what kind of treatment they're testing: oral immunotherapy, a biologic, or a mix of both. Eligibility and what's involved can look very different between these, so it's worth knowing which type you're looking at.
Right now, you can find studies testing a new peanut medicine called ENP-501, and an early study looking at gut bacteria called VE416. Our peanut allergy clinical trials page always shows which studies are recruiting right now. Applying takes about 5 minutes, and a coordinator will follow up to see if you're a good fit.
Common questions
What are the symptoms of a peanut allergy? Symptoms range from mild, hives, tingling in the mouth, mild stomach upset, to severe, throat swelling, trouble breathing, and anaphylaxis. Reactions can look different each time, even in the same person.
What does a peanut allergy rash look like? It usually appears as raised, red, itchy welts (hives) that can show up within minutes of exposure, often around the mouth first if the exposure was from eating, though a rash alone isn't always a sign of a severe reaction.
How do you know if a baby has a peanut allergy? Signs in babies can include hives, vomiting, or swelling shortly after eating peanut for the first time. Any suspected reaction in an infant should be evaluated by a pediatrician or allergist rather than tested again at home.
Is the Viaskin patch available anywhere right now? No. It remains investigational and unapproved as of this writing, despite positive recent trial results. A new approval submission is planned but hasn't happened yet.
Can someone try a patch and oral immunotherapy at the same time? Not typically within a single trial, most study designs test one approach at a time to clearly measure its effect, though real-world clinical care sometimes combines strategies under a specialist's guidance outside of a trial setting.